Remove Drug Development Remove Pharma Companies Remove Therapies
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

article thumbnail

Best CDMO Practices for Startups: Navigating the Complex World of Contract Development and Manufacturing

Drug Patent Watch

Navigating the complex landscape of drug development and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. This can offer advantages in terms of continuity and efficiency.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

Drug repurposing’s potential to target undruggable molecules is showing huge promise for its ability to accelerate the development of new therapies and improve patient outcomes. They also provide a level playing field for academics, biotech companies, and pharma giants to compete on.

Drugs 98
article thumbnail

Zebrafish for Disease Modeling and Drug Screening in Pediatric Cancers

biobide

Children and adolescents lack robust preclinical models to replicate the pathologies and provide precise and targeted therapies. This is why not many Pharma companies specifically specialize in discovering and developing pediatric cancer treatments; a great example of advancing new therapies for childhood cancer is the biotech Oncoheroes.

Disease 59
article thumbnail

Algae: a source for prebiotics and drugs to treat IBD

Drug Target Review

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75
article thumbnail

H1’s Predictions for Healthcare and Pharma in 2025

H1 Blog

Drug Policy There will be significant changes in clinical trials & drug development due to the Inflation Reduction Act. As pharmaceutical companies shift their focus toward fewer, high-value therapeutic areas in light of the IRAs drug price negotiations, the overall number of clinical trials will go down.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

As pharma companies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces.